Intensity Therapeutics restarts Phase 2 INVINCIBLE-4 breast cancer trial, doses first patients in Switzerland
INTS•Enrollment target
The trial targets 47 additional patients in Switzerland and France.
Study design and endpoint
The study compares INT230-6 before standard neoadjuvant immuno-chemotherapy versus standard-of-care alone, with pathological complete response as the primary endpoint.
Prior dosing and safety trend
Fourteen patients were treated before the pause; the INT230-6 arm showed a favorable trend toward fewer grade 3+ adverse events versus standard-of-care alone.
Trial restarts in Switzerland
Intensity Therapeutics restarted dosing in its randomized Phase 2 INVINCIBLE-4 presurgical triple-negative breast cancer trial in Switzerland.
Enrollment resumes following a pause to assess skin irritation; the amended regimen uses a lower drug-to-tumor ratio and a single INT230-6 injection.
